This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van den Berghe, G. Articles by Bowers, C. Y. Search for Related Content PubMed PubMed Citation Articles by Van den Berghe, G. Articles by Bowers, C. Y.

Leptin Levels in Protracted Critical Illness: Effects of Growth Hormone-Secretagogues and Thyrotropin-Releasing Hormone¹

Departments of Intensive Care Medicine (G.V.d.B., P.W.) and Medicine, Division of Endocrinology (R.B.), University Hospital Gasthuisberg, University of Leuven, B-3000 Leuven, Belgium; Research Center for Endocrinology and Metabolism (L.C.), Department of Internal Medicine, Sahlgrenska University Hospital, 5-41345 Göteborg, Sweden; Kolling Institute (R.C.B.), University of Sydney, SW2065 St. Leonards, Australia; and Department of Medicine (C.Y.B.), Division of Endocrinology, Tulane University Medical Center, New Orleans, Louisiana 70112-2699

Address all correspondence and requests for reprints to: Greet Van den Berghe, M.D., Ph.D., Department of Intensive Care Medicine, University Hospital Gasthuisberg, University of Leuven, B-3000 Leuven, Belgium. E-mail: greta.vandenberghe{at}uz.kuleuven.ac.be

Prolonged critical illness is characterized by feeding-resistant wasting of protein, whereas reesterification, instead of oxidation of fatty acids, allows fat stores to accrue and associate with a low-activity status of the somatotropic and thyrotropic axis, which seems to be partly of hypothalamic origin.

To further unravel this paradoxical metabolic condition, and in search of potential therapeutic strategies, we measured serum concentrations of leptin; studied the relationship with body mass index, insulin, cortisol, thyroid hormones, and somatomedins; and documented the effects of hypothalamic releasing factors, in particular, GH-secretagogues and TRH.

Twenty adults, critically ill for several weeks and supported with normocaloric, continuously administered parenteral and/or enteral feeding, were studied for 45 h. They had been randomized to receive one of three combinations of peptide infusions, in random order: TRH (one day) and placebo (other day); TRH + GH-releasing peptide (GHRP)-2 and GHRP-2; TRH + GHRH + GHRP-2 and GHRH + GHRP-2. Peptide infusions were started after a 1-µg/kg bolus at 0900 h and infused (1 µg/kg·h) until 0600 h the next morning. Serum concentrations of leptin, insulin, cortisol, T₄, T₃, insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the acid-labile subunit (ALS) were measured at 0900 h, 2100 h, and 0600 h on each of the 2 study days.

Baseline leptin levels (mean ± SEM: 12.4 ± 2.1 µg/L) were independent of body mass index (25 ± 1 kg/m²), insulin (18.6 ± 2.9 µIU/mL), cortisol (504 ± 43 mmol/L), and thyroid hormones (T₄: 63 ± 5 nmol/L, T₃: 0.72 ± 0;08 nmol/L) but correlated positively with circulating levels of IGF-I [86 ± 6 µg/L, determination coefficient (R²) = 0.25] and ALS (7.2 ± 0.6 mg/L, R² = 0.32). Infusion of placebo or TRH had no effect on leptin. In contrast, GH-secretagogues elevated leptin levels within 12 h. Infusion of GHRP-2 alone induced a maximal leptin increase of +87% after 24 h, whereas GHRH + GHRP-2 elevated leptin by up to +157% after 36 h. The increase in leptin within 12 h was related (R² = 0.58) to the substantial rise in insulin. After 45 h, and having reached a plateau, leptin was related to the increased IGF-I (R² = 0.37).

In conclusion, circulating leptin levels during protracted critical illness were linked to the activity state of the GH/IGF-I axis. Stimulating the GH/IGF-I axis with GH-secretagogues increased leptin levels within 12 h. Because leptin may stimulate oxidation of fatty acids, and because GH, IGF-I, and insulin have a protein-sparing effect, GH-secretagogue administration may be expected to result in increased utilization of fat as preferential substrate and to restore protein content in vital tissues and, consequently, has potential as a strategy to reverse the paradoxical metabolic condition of protracted critical illness.

This article has been cited by other articles:

				L. GHIZZONI and G. MASTORAKOS Interactions of Leptin, GH, and Cortisol in Normal Children Ann. N.Y. Acad. Sci., November 1, 2003; 997(1): 56 - 63. [Abstract] [Full Text] [PDF]

				K. C McCowen, P. R. Ling, C. Friel, J. Sternberg, R A. Forse, P. A Burke, and B. R Bistrian Patterns of plasma leptin and insulin concentrations in hospitalized patients after the initiation of total parenteral nutrition Am. J. Clinical Nutrition, May 1, 2002; 75(5): 931 - 935. [Abstract] [Full Text] [PDF]

				P. Marzullo, C. Buckway, K. L. Pratt, A. Colao, J. Guevara-Aguirre, and R. G. Rosenfeld Leptin Concentrations in GH Deficiency: The Effect of GH Insensitivity J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 540 - 545. [Abstract] [Full Text] [PDF]

				R. Coutant, F. Boux de Casson, S. Rouleau, O. Douay, E. Mathieu, M. Audran, and J. M. Limal Body Composition, Fasting Leptin, and Sex Steroid Administration Determine GH Sensitivity in Peripubertal Short Children J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5805 - 5812. [Abstract] [Full Text] [PDF]

				L. Ghizzoni, G. Mastorakos, M. E. Street, G. Mazzardo, A. Vottero, M. Vanelli, and S. Bernasconi Leptin, Cortisol, and GH Secretion Interactions in Short Normal Prepubertal Children J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3729 - 3734. [Abstract] [Full Text] [PDF]

				N. LAMEIRE and R. VANHOLDER Pathophysiologic Features and Prevention of Human and Experimental Acute Tubular Necrosis J. Am. Soc. Nephrol., February 1, 2001; 12(90001): 20S - 32. [Abstract] [Full Text]

				M. S. Gill, A. A. Toogood, J. Jones, P. E. Clayton, and S. M. Shalet Serum Leptin Response to the Acute and Chronic Administration of Growth Hormone (GH) to Elderly Subjects with GH Deficiency J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1288 - 1295. [Abstract] [Full Text]

				G. Van den Berghe, P. Wouters, F. Weekers, S. Mohan, R. C. Baxter, J. D. Veldhuis, C. Y. Bowers, and R. Bouillon Reactivation of Pituitary Hormone Release and Metabolic Improvement by Infusion of Growth Hormone-Releasing Peptide and Thyrotropin-Releasing Hormone in Patients with Protracted Critical Illness J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1311 - 1323. [Abstract] [Full Text]